Policy & Regulation
AstraZeneca rare disease unit secures US and EU approvals for Klygefa in myasthenia gravis
17 November 2026 -

Biopharmaceutical company AstraZeneca PLC (STO: AZN; LON: AZN; NYSE: AZN) said on Monday that Alexion, AstraZeneca Rare Disease's Klygefa (gefurulimab) has been approved in both the US and the European Union for adults with anti-acetylcholine receptor antibody-positive generalised myasthenia gravis (gMG).

The treatment is a dual-binding nanobody C5 inhibitor administered once weekly by subcutaneous autoinjector.

Both approvals were supported by results from the Phase III PREVAIL trial, in which Klygefa met its primary endpoint, demonstrating an improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) total score at week 26 versus placebo (treatment difference: -1.6 [95% CI: -2.4, -0.8], p

Login
Username:

Password: